-

12:03:47 AM

ATHE Stock News

ATHE - Alterity Therapeutics Ltd

06/23/22 11:00 AM

Nasdaq : ATHE

clinical trial

Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in Italy

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the Italian Medicines

RHEA-AI

neutral

06/02/22 8:00 AM

Nasdaq : ATHE

clinical trial

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease

RHEA-AI

neutral

04/27/22 7:40 AM

Nasdaq : ATHE

clinical trial

Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in the United Kingdom

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the United Kingdom Medicines &

RHEA-AI

neutral

04/06/22 9:34 PM

Nasdaq : ATHE

Alterity Therapeutics Announces Presentation of bioMUSE Data at the American Academy of Neurology (AAN) Annual Meeting

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments

RHEA-AI

neutral

03/07/22 7:59 AM

Nasdaq : ATHE

conferences

Alterity Therapeutics to Present at the 34th Annual Roth Conference

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D.,

RHEA-AI

neutral

01/28/22 7:08 AM

Nasdaq : ATHE

Alterity Therapeutics Announces Publication Demonstrating that ATH434 is Neuroprotective in Animal Model of Parkinsonian Disorder in the Journal of Parkinson's Disease

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that data in an animal model of Multiple

RHEA-AI

neutral

01/27/22 7:45 AM

Nasdaq : ATHE

Appendix 4C - Q2 FY22 Quarterly Cash Flow Report

Highlights:NZ's regulator Medsafe authorizes Phase 2 clinical trial for ATH434; more jurisdictions to follow New poster presentation and publications provide further evidence of potential of ATH434 to treat neurodegenerative diseases New US composition of matter patent secures exclusivity for a

RHEA-AI

neutral

01/06/22 7:30 AM

Nasdaq : ATHE

Alterity Therapeutics Granted New US Patent for Compounds for Neurodegenerative Diseases Including Parkinson's and Alzheimer's

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the United States Patent

RHEA-AI

very positive

01/05/22 7:45 AM

Nasdaq : ATHE

conferences

Alterity Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive

RHEA-AI

neutral

12/14/21 7:25 AM

Nasdaq : ATHE

clinical trial

Alterity Therapeutics Announces First Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced that the New Zealand Medicines and Medical

RHEA-AI

neutral